Airway antibodies wane rapidly after COVID-19 but B cell memory is generated across disease severity

Alberto Cagigi[1], Meng Yu[1], Sara Falck-Jones[1], Sindhu Vangeti[1], Björn Österberg[1], Eric Åhlberg[1], Lida Azizmohammadi[1], Ryan Falck-Jones[2,3], Pia C Gubisch[1], Mert Ödemis[1], Farangies Ghafoor[1], Klara Lenart[1], Max Bell[2,3], Niclas Johansson[4,5], Jan Albert[6,7], Jörgen Sälde[8], Deleah Pettie[9,10], Michael Murphy[9,10], Lauren Carter[9,10], Neil P King[9,10], Sebastian Ols[1], Anna Färnert[4,5], Karin Loré[1*] and Anna Smed-Sörensen[1*]

[1]Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. [2]Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden. [3]Department of Perioperative Medicine and Intensive Care, Karolinska University Hospital, Stockholm, Sweden. [4]Division of Infectious Diseases, Department of Medicine Solna, Center for Molecular Medicine, Karolinska Institutet, Sweden. [5]Department of Infectious Diseases, Karolinska University Hospital Solna, Stockholm, Sweden. [6]Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden. [7]Clinical Microbiology, Karolinska University Hospital Solna, Stockholm, Sweden. [8]Närakut SLSO, Karolinska University Hospital Solna, Stockholm, Sweden. [9]Department of Biochemistry, University of Washington, Seattle, WA 98195, United States. [10]Institute for Protein Design, University of Washington, Seattle, WA 98195, United States.

Karin Lore´ and Anna Smed-Sörensen contributed equally to this study.

***Corresponding authors:**
Karin Loré and Anna Smed-Sörensen, Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet, Visionsgatan 4, BioClinicum J7:30, Karolinska University Hospital, 171 64 Stockholm, Sweden.
e-mail addresses: karin.lore@ki.se; anna.smed.sorensen@ki.se

Introductory paragraph:

Understanding immune responses following SARS-CoV-2 infection in relation to COVID-19 severity is critical to predicting the effects of long-term immunological memory on viral spread. Here we longitudinally assessed systemic and airway immune responses against SARS-CoV-2 in a well-characterized cohort of 147 infected individuals representing the full spectrum of COVID-19 severity; from asymptomatic infection to fatal disease. High systemic and airway antibody responses were elicited in patients with moderate to severe disease, and while systemic IgG levels were maintained after acute disease, airway IgG and IgA declined significantly. In contrast, individuals with mild symptoms showed significantly lower antibody responses but their levels of antigen-specific memory B cells were comparable with those observed in patients with moderate to severe disease. This suggests that antibodies in the airways may not be maintained at levels that prevent local virus entry upon re-exposure and therefore protection via activation of the memory B cell pool is critical.

Main:

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection that causes coronavirus disease 2019 (COVID-19) can present with a wide range of disease severity from asymptomatic to fatal. Individuals of advanced age and/or those with comorbidities are overrepresented among those who develop severe disease[1]. However, the majority of SARS-CoV-2 infected individuals experience asymptomatic infection or only mild disease[2]. Whether patients with different disease severities generate similar protective immunity is still unknown. Here we present data generated from a clinically well-characterized cohort of individuals with SARS-CoV-2 infection (n=147) representing the full spectrum of COVID-19 severity ranging from asymptomatic infection to fatal disease. Individuals were sampled during acute disease and convalescence with longitudinal, matched blood and airway samples. The levels of systemic and airway antibody responses as well as the generation of SARS-CoV-2-specific memory B cells were measured. Plasma, peripheral blood mononuclear cells (PBMC), nostril swabs (NSW) and nasopharyngeal aspirates (NPA) were collected across all disease severities whereas endotracheal aspirates (ETA) were collected only from intubated patients receiving intensive care (Figure 1a). Disease severity was assessed on a seven-point scale derived from the respiratory domain of the sequential organ failure assessment (SOFA) score[3,4], with additional levels for non-admitted mild cases (1) and fatal cases (7). Patients were grouped based on peak disease severity (PDS) (Supplementary table 1 and online methods). In addition, pre-pandemic healthy controls (PPHC) (n=30) as well as individuals who experienced influenza-like symptoms and were possibly exposed to SARS-Cov-2 but had a negative diagnostic PCR (PCR-) (n=9) were sampled in the same way and included as controls (Supplementary table 2 and online methods).

We first assessed systemic IgG and IgA responses at the time of study inclusion that ranged between 0-54 days from onset of symptoms; median 16 days, and at the first follow-up visit during convalescence (46-168 days; median 108 days). Plasma IgG and IgA against the SARS-CoV-2 nucleocapsid (N) and spike (S) proteins as well as the receptor binding domain (RBD)[5,6] of the S protein were measured by ELISA. Antibody responses against the internal N protein have been shown to be elevated in deceased individuals but whether these antibodies contribute to disease severity is unknown[7,8]. In contrast, responses against the viral surface protein S and, in particular, against the RBD result in virus neutralization[9]. Responses against the RBD are thus likely necessary for protection from re-infection or prevention of symptomatic disease.

In line with previous reports[7,8,10-12], IgG and IgA responses against N, S and RBD were robust in acute disease in the majority of individuals with moderate to severe disease while they were substantially lower in individuals with mild disease (Figure 1b). However, in our cohort, this might also partially be due to earlier study inclusion of patients with mild symptoms (median days from onset of symptoms 11 as compared with 13 and 21.5 in the moderate and severe groups respectively, and 13 in the fatal group) (Supplementary table 1). In fact, while IgG levels remained high in the patients with moderate to severe disease in the convalescent phase, levels had increased in the individuals with mild disease. In contrast, IgA levels from the acute phase, against all antigens, waned substantially during convalescence in most patients (Figure 1b and supplementary fig. 1a). While the levels of IgG against the RBD (Figure 1c), as well as against N and S (Supplementary fig. 1b), exhibited a positive

correlation with days from onset of symptoms during the acute phase, this was less pronounced for IgA levels. Altogether, these data confirm that the generation of IgA likely precede that of IgG. Earlier reports of individuals with asymptomatic infection or mild disease also showed robust early IgA responses[13-15].

Comparably to another study[16], the levels of both IgG and IgA against all antigens tested, during both acute disease and convalescence, correlated directly with disease severity (Supplementary fig. 2a), indicating that individuals with severe disease or even fatal outcome mounted the highest antibody responses against SARS-CoV-2 antigens. In our cohort, this is further supported by the fact that the patients with moderate/severe disease and fatal outcome for whom we initially observed low IgG titers against RBD, had an early study inclusion (on average 13 days from onset of symptoms); but showed significantly higher titers later during the acute phase (on average 19 days) (Figure 1d-e). Similar kinetics of anti-RBD responses have previously been noted in different patient cohorts[17-19].

In line with previous reports, the Charlson Comorbidity Index (CCI) and the Body Mass Index (BMI) were associated with disease severity[1] in the cohort (Supplementary fig. 3). However, the presence of comorbidities did not impact the ability to generate antibodies against any of the antigens analyzed (Supplementary fig. 2b).

As the respiratory tract is the initial site of viral infection and replication, we next measured the levels of IgG and IgA in the upper and lower airways and compared with levels in plasma at matched time points. Due to limited sample volumes, we focused our analyses on IgG and IgA responses against the RBD since these responses are likely most critical for virus neutralization. We found that RBD-specific antibodies could be readily detected in NSW and NPA during the acute phase in several patients across all disease severities (Figure 2a-b and supplementary fig. 4a). In agreement with our observations in plasma, antibody levels in the upper respiratory tract were higher in patients with moderate or severe disease as compared with individuals with mild disease (Figure 2a-b). Both IgG and IgA levels declined significantly in the convalescent phase, with IgG declining to almost undetectable levels (Figure 2a-b). This demonstrates that airway antibody levels wane much faster than those in plasma during convalescence. Low but detectable levels of antibodies to SARS-CoV-2 have previously been reported also in saliva during convalescence[20]. However, whether these low antibody levels at mucosal sites will be sufficient for protection is not known. We found that RBD-specific IgG and IgA levels in the respiratory tract correlated well with those in plasma during the acute phase but to a lesser extent during convalescence (Supplementary fig. 4b and supplementary fig. 5). When comparing matched NSW, NPA and ETA collected at the same time point during acute disease from intubated patients, significantly higher levels of IgA against the RBD were found in NPA as compared with NSW and ETA (Figure 2c). While this could be partially influenced by differences in sampling method and sample volume, these data suggest that antibody abundance and possibly virus neutralization via IgA differs along the respiratory tract and may be more pronounced in the nasopharynx compared to the lower airways. Hence, nasopharynx antibodies (both IgG and IgA) showed a strong correlation with plasma antibody responses (Supplementary fig. 4b and supplementary fig. 5). We also assessed the presence of B cells in the respiratory tract of COVID-19 patients by analyzing the lymphocytes that could be retrieved from NPA and ETA as compared with NPA from three healthy controls (HC). Lymphocyte frequencies were lower in both NPA and ETA

142 from several COVID-19 patients as compared with NPA from HC. However, the relative
143 proportion of B cells was not different. In addition, we observed that in the COVID-19
144 patients, the frequencies of B cells were higher in NPA as compared with ETA which possibly
145 contributes to the higher antibody levels at this site (Supplementary fig. 6).
146
147 Altogether, the data presented so far confirm that moderate and severe COVID-19 result in
148 high levels of circulating antibodies and show that despite IgG being well-maintained during
149 convalescence, antibody levels in the airways decline significantly after the acute phase.
150 Generally, antibodies present in circulation and at local sites are the result of secretion from
151 short-lived plasmablasts and/or terminally differentiated plasma cells in the bone marrow or
152 mucosal sites[21]. The response to a secondary infection once antibody titers have waned
153 below protective levels mostly relies on the presence of resting antigen-specific memory B
154 cells that are rapidly activated upon antigen re-exposure[21]. We therefore investigated the
155 induction and maintenance of antigen-specific memory B cells similar to other studies[22-24].
156 We focused on the direct comparison between individuals with mild disease and patients
157 with moderate/severe disease, along with individuals who had reported mild influenza-like
158 symptoms but were SARS-CoV-2 PCR-. Patients with moderate/severe disease who had high
159 circulating IgG and IgA levels were specifically selected for the analysis to be able to compare
160 the opposite ends of the COVID-19 disease spectrum. Matched PBMC from acute disease
161 and convalescence were analyzed side-by-side using fluorescently labelled S and RBD probes
162 to detect antigen-specific B cells[22-24]. Patients with moderate/severe disease had switched
163 memory B cells specific to S in the acute phase and the memory B cell pool had further
164 expanded in the convalescent phase (ranging from 0.009 to 1.35%; mean 0.42% during
165 convalescence) (Figure 2d-e). Individuals with mild disease showed lower memory B cells
166 during acute disease than the patients with moderate/severe disease, but the levels had
167 increased by the time of convalescent sampling (ranging from 0.17% to 0.64%; mean 0.35%
168 during convalescence) and were comparable between the groups (Figure 2d-e and
169 supplementary fig. 6). Further phenotyping of the S-specific memory B cells indicated that
170 the majority of these cells may be specific for epitopes on S outside of the RBD (Figure 2f).
171 However, it is possible that binding of B cells to RBD could be underestimated as RBD is also
172 present in the S protein. S-specific memory B cells in the circulation were predominantly
173 IgG+, rather than IgA+ (Figure 2f). Low frequencies of S and RBD-specific memory B cells
174 were observed in the PCR- individuals (Figure 2e). However, these were not significantly
175 different from the levels observed in PPHC (Supplementary fig. 7). Collectively, since the
176 majority of individuals infected with SARS-CoV-2 are either asymptomatic or experience only
177 mild COVID-19 symptoms[2], the possibility of generating antigen-specific memory B cells
178 without experiencing severe disease, would be very important in the prospect of
179 establishing potential immunity at the population level.
180
181 In summary, here we show that COVID-19 disease severity not only determines the
182 magnitude of systemic but also airway antibody levels with efficient generation of virus-
183 specific memory B cells against SARS-CoV-2 also occurring upon mild disease. While plasma
184 IgG levels were generally well detectable at convalescence in all groups, there was a
185 significant decline in airway antibodies after the clearance of infection. This suggests that
186 antibodies in the airways may not be maintained at levels that prevent local virus entry upon
187 re-exposure. However, our data indicate that the majority of infected individuals have the
188 ability to generate anamnestic responses via the memory B cell pool and thereby may be

protected or mitigate disease severity. Whether sufficient number of memory B cells will be maintained long-term and to what extent they will prevent the spread of SARS-CoV-2 at the population level remain to be understood. This is critical knowledge to acquire in the near future to evaluate together with the memory B cell response generated after the introduction of SARS-CoV-2 vaccination. Ultimately, the requirements for establishment of long-term protection and immunity will need to be determined.

Methods

Study design, patient enrollment and sample collection

One hundred and forty-seven (147) PCR-confirmed SARS-CoV-2 infected patients were enrolled at the Karolinska University Hospital and Haga Outpatient Clinic (Haga Närakut), Stockholm, Sweden during March-May 2020 (acute phase) and during April-September 2020 (convalescence). Patients were enrolled at various settings, ranging from primary to intensive care. In order to recruit asymptomatic and mild cases, household contacts of COVID-19 patients were screened with PCR and enrolled if positive. A small subset of these individuals who experienced influenza-like symptoms and were possibly exposed to SARS-Cov-2 but had a negative diagnostic PCR (PCR-) (n=9 of whom 3 were household contacts of confirmed patients, 4 had symptoms including fever and 2 had symptoms but no fever) were sampled in the same way and included as controls alongside with 30 pre-pandemic healthy control samples (PPHC) from 2016-2018.

Respiratory failure was categorized daily according to the respiratory domain of the Sequential Organ Failure Assessment score (SOFA)[3]. The modified SOFA score (mSOFA) was calculated when arterial partial pressure of oxygen (PaO_2) was not available. In this case peripheral transcutaneous hemoglobin saturation (SpO_2) was used instead[4]. Estimation of the fraction of inspired oxygen (FiO_2) based on O_2 flow was calculated as per the Swedish Intensive Care register definition[25]. Patients were categorized based on the peak respiratory SOFA or mSOFA value with the 5-point respiratory SOFA score being extended with additional levels to include and distinguish admitted asymptomatic and non-admitted/admitted mild cases and to include fatal outcome added as a seventh level. Ten (10) patients with fatal outcome had peak disease severity score 6 prior to death and 2 patients had scores of 4 and 5. For convenience, the resulting 7-point composite peak disease severity (PDS) was condensed into a broader classification consisting of mild (1-2), moderate (3-4), severe (5-6), and fatal (7). Demographics and additional data were collected from medical records, including clinical history and risk factors such as BMI and co-morbidities. Total burden of comorbidities was assessed using the Charlson co-morbidity index (CCI)[26] (Supplementary table 1). Additional clinical information on this patient cohort can also be found in Falck-Jones et al[27].

Blood was collected in EDTA-containing tubes from all patients except those admitted to the intensive care unit (ICU) for whom blood was pooled from heparin-coated blood gas syringes discarded in the last 12 hours. For some ICU patients, additional venous blood was also collected in EDTA tubes. Nostril swabs (NSW) and nasopharyngeal aspirates (NPA) were collected from the majority of the patients whereas endotracheal aspirates (ETA) were only collected from patients with mechanical ventilation intubated in the ICU. Admitted patients

were sampled during acute disease at up to four timepoints and ICU patient material was collected up at to ten timepoints. For this study, unless otherwise stated, the measurements referring to acute disease were performed with samples collected at the time of study inclusion and during convalescence when patients returned for a follow-up visit.

The study was approved by the Swedish Ethical Review Authority, and performed according to the Declaration of Helsinki. Written informed consent was obtained from all patients and controls. For sedated patients, the denoted primary contact was contacted and asked about the presumed will of the patient and to give initial oral and subsequently signed written consent. When applicable retrospective written consent was obtained from patients with non-fatal outcomes.

Enzyme-linked immunosorbent assay (ELISA)

The presence of IgG or IgA binding against the SARS-Cov-2 Nucleocapsid (N) and Spike (S) trimer or the Receptor Binding Domain (RBD) monomer[5] in plasma and airway samples was assessed by enzyme-linked immunosorbent assay (ELISA). Recombinant proteins were received through the global health-vaccine accelerator platforms (GH-VAP) funded by the Bill & Melinda Gates Foundation. Briefly, 96-half well plates were coated with 50ng/well of the respective protein. Plates were incubated with a selected duplicate dilution that did not provide background noise against ovalbumin used as a negative control (data not shown) (i.e. 1:20 for plasma samples, 1:2 for NSW and NPA, and 1:5 for ETA in 5% milk/PBS buffer). Duplicate 7-point serial dilutions were initially performed for measuring plasma IgG against RBD during acute disease and the half maximal effective concentration (EC_{50}) was calculated using GraphPad Prism 9. However, since for several samples with low antibody concentration (mostly from the asymptomatic/mild category) the EC_{50} was below the highest dilution used (of 1:20) and therefore below the limit of detection (Supplementary fig. 8a), the maximal optical density (OD) at 1:20 dilution was used instead for this and for all the other measurements subsequently performed. The relation with maximal OD and EC_{50} was also verified in a subset of patients with high IgG and IgA against S (Supplementary fig. 8b). Detection was performed with mouse and goat anti-human IgG or IgA HRP-conjugated secondary antibodies (clone G18-145 from BD Biosciences and polyclonal from ThermoFisher, respectively) followed by incubation with TMB substrate (BioLegend) which was stopped with a 1M solution of sulfuric acid. Blocking with 5% milk/PBS buffer and washing with 0.1% Tween-20/PBS buffer were performed between each step. Absorbance was read at 450nm and background correction at 550nm using an ELISA reader. Data were reported as maximal absorbance i.e. OD, as stated above, and plotted using GraphPad Prism 9. All of the antibody measurements in plasma and respiratory samples from SARS-CoV-2 patients were run alongside with samples from two different control groups as described above. Interestingly, low but readily detectable IgA reactivity against S was detected in the pre-pandemic healthy controls and in the PCR- individuals (Supplementary fig. 8b). After having verified the specificity and sensitivity of our ELISA assay for IgA detection with limiting sample dilutions (Supplementary fig. 8c), we hypothesize that this might be due to cross-reactivity on the shared portions of the S protein between SARS-CoV-2 and other common cold coronaviruses. Reports have shown that cross-reactivity between coronaviruses exists[28,29].

Flow cytometry

Staining of cells from airway samples was performed fresh. Briefly, samples were centrifuged at 400 g for 5 min at room temperature and cells were washed with sterile PBS. Mucus was removed using a 70 μm cell strainer and cells were subsequently stained with the appropriate combination of fluorescently labelled monoclonal antibodies as illustrated in Supplementary table 3a. Staining of PBMC was performed on previously cryopreserved samples. The appropriate combination of fluorescently labelled monoclonal antibodies binding to different cell surface markers and with fluorescently labelled S and RBD proteins used as probes for antigen-specific B cells is illustrated in Supplementary table 3b. Probes were prepared from biotinylated proteins using a 4:1 molar ratio (protein:fluorochrome-labelled streptavidin) considering the molecular weight of protein monomers and of the streptavidin only. The probes were prepared using streptavidin conjugated to PE and APC for S and with BV421 for the RBD. The gating strategy for the identification of antigen-specific memory B cells is shown in Figure 2d. Briefly, after identification of lymphocytes in single suspension, live B cells, (i.e. cells not expressing CD3/,CD14/CD16/CD56) were gated. From this gate, B cells were further isolated by expression of CD19 and CD20 and then switched memory B cells were identified as IgD-IgM-. From these, S-specific switched memory B cells were identified by binding to both S protein probes. Further characterization was then carried out by analyzing IgG expression (IgA+ switched memory B cells are assumed to mirror IgD-IgM-IgG- B cells) and fluorescently labelled RBD. Stained cells from airway samples were acquired using a BD LSRFortessa while stained PBMC were acquired using a BD FACSAria Fusion both interfaced with the BD FACSDiva Software. Results were analyzed using BD FlowJo version 10.

Statistical analyses

All statistical analyses were performed using GraphPad Prism 9. Spearman correlation was used to assess the interdependence of 2 different non-categorical parameters across individuals whereas Wilcoxon matched-pairs signed rank or Mann–Whitney U tests as appropriate, were used to assess differences or similarities for one single parameter between 2 different groups. Kruskal -Wallis with Dunn's multiple comparisons test was used when assessing comparison between multiple groups.

Acknowledgments

We thank the patients and healthy volunteers who have contributed to this study. We would also like to thank medical students and hospital staff for assistance with patient sampling and collection of clinical data, the Biomedicum BSL3 core facility, Karolinska Institutet and Fredrika Hellgren for assistance with English editing. This work was supported by grants from the Swedish Research Council, the Swedish Heart-Lung Foundation, the Bill & Melinda Gates Foundation, the Knut and Alice Wallenberg Foundation through SciLifeLab and Karolinska Institutet.

Author contributions

Experimental study design: A.C., Ka.L. and A.S-S. Clinical concept design: A.S-S., M.B., N.J., J.A., J.S. and A.F. Acquisition and sample processing: M.Y., S. F-J., S.V., B.Ö., E.Å., L.A., R.F-J., M.Ö. and F.G. Generation of data: A.C., M.Y., S. F-J., S.V. and P.C.G. Provision of custom reagents: D.P., M.M., L.C., and N.P.K. Analysis and interpretation of data: A.C., Ka.L. and A.S-S. Critical revision of the manuscript: all authors. Statistical analysis: A.C., K.L. and S.O. Ka.L. and A.S-S. contributed equally to the study.

Competing interests

The authors declare no competing financial interests.

References

1. Zaki, N., Alashwal, H. & Ibrahim, S. Association of hypertension, diabetes, stroke, cancer, kidney disease, and high-cholesterol with COVID-19 disease severity and fatality: A systematic review. *Diabetes Metab Syndr* **14**, 1133-1142 (2020).
2. Moghadas, S.M.*, et al.* The implications of silent transmission for the control of COVID-19 outbreaks. *Proc Natl Acad Sci U S A* (2020).
3. Vincent, J.L.*, et al.* The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. *Intensive Care Med* **22**, 707-710 (1996).
4. Grissom, C.K.*, et al.* A modified sequential organ failure assessment score for critical care triage. *Disaster Med Public Health Prep* **4**, 277-284 (2010).
5. Walls, A.C.*, et al.* Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell* **181**, 281-292 e286 (2020).
6. Wrapp, D.*, et al.* Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science* **367**, 1260-1263 (2020).
7. Atyeo, C.*, et al.* Distinct Early Serological Signatures Track with SARS-CoV-2 Survival. *Immunity* **53**, 524-532 e524 (2020).
8. Guthmiller, J.J.*, et al.* SARS-CoV-2 infection severity is linked to superior humoral immunity against the spike. *bioRxiv* (2020).
9. Piccoli, L.*, et al.* Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. *Cell* (2020).
10. Zhao, J.*, et al.* Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. *Clin Infect Dis* **71**, 2027-2034 (2020).
11. Gudbjartsson, D.F.*, et al.* Humoral Immune Response to SARS-CoV-2 in Iceland. *N Engl J Med* **383**, 1724-1734 (2020).
12. Gaebler, C.*, et al.* Evolution of Antibody Immunity to SARS-CoV-2. *bioRxiv* (2020).
13. Cervia, C.*, et al.* Systemic and mucosal antibody secretion specific to SARS-CoV-2 during mild versus severe COVID-19. *bioRxiv*, 2020.2005.2021.108308 (2020).
14. Staines, H.M.*, et al.* Dynamics of IgG seroconversion and pathophysiology of COVID-19 infections. *medRxiv* (2020).

15. Sterlin, D.*, et al.* IgA dominates the early neutralizing antibody response to SARS-CoV-2. *medRxiv* (2020).
16. Hansen, C.B.*, et al.* SARS-CoV-2 Antibody Responses Are Correlated to Disease Severity in COVID-19 Convalescent Individuals. *J Immunol* (2020).
17. Rydyznski Moderbacher, C.*, et al.* Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. *Cell* (2020).
18. Lynch, K.L.*, et al.* Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship to disease severity. *Clin Infect Dis* (2020).
19. Robbiani, D.F.*, et al.* Convergent antibody responses to SARS-CoV-2 in convalescent individuals. *Nature* (2020).
20. Isho, B.*, et al.* Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. *Sci Immunol* **5**(2020).
21. Zielinski, C.E.*, et al.* Dissecting the human immunologic memory for pathogens. *Immunol Rev* **240**, 40-51 (2011).
22. Dan, J.M.*, et al.* Immunological memory to SARS-CoV-2 assessed for greater than six months after infection. *bioRxiv*, 2020.2011.2015.383323 (2020).
23. Rodda, L.B.*, et al.* Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. *medRxiv* (2020).
24. Juno, J.A.*, et al.* Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. *Nat Med* (2020).
25. Intensivvårdsregistret, S. SIR:s riktlinje för registrering av SOFA. . (2018).
26. Charlson, M.E., Pompei, P., Ales, K.L. & MacKenzie, C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* **40**, 373-383 (1987).
27. Falck-Jones, S.*, et al.* Functional myeloid-derived suppressor cells expand in blood but not airways of COVID-19 patients and predict disease severity. *medRxiv* (2020).
28. Grifoni, A.*, et al.* Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. *Cell* **181**, 1489-1501 e1415 (2020).
29. Song, G.*, et al.* Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection. *bioRxiv* (2020).

407 **Figure legends**
408
409 **Figure 1. Plasma IgG and IgA responses to N, S and RBD across COVID-19 severity during**
410 **acute disease and convalescence.**
411 **a)** Overview of study cohort and controls, timeline of longitudinal sampling, the anatomical
412 compartments analyzed, and the measurements performed. AS=asymptomatic. **b)** Scatter
413 plots show individual levels of plasma IgG and IgA (from left to right) in SARS-CoV-2 infected
414 individuals with different peak disease severity (PDS). Data in cyan and green refer to mild
415 disease (PDS 1 and 2), yellow and orange refer to moderate disease (PDS 3 and 4), red and
416 cayenne refer to severe disease (PDS 5 and 6) and grey refers to patients with fatal outcome
417 (PDS 7). Black lines indicate medians and dotted lines indicate the average background level
418 from PPHC. Mann-Whitney U was used to compare the groups. **c)** Spearman correlation for
419 plasma immunoglobulins against the RBD versus days from onset of symptoms during the
420 acute and the convalescent phases are shown. Circles with black lining refer to convalescent
421 samples. **d-e)** Longitudinal measurements of plasma IgG against RBD on a subset of patients
422 with moderate/severe disease and fatal outcome who had low antibody titers at the time of
423 study inclusion. Levels are shown at the time of study inclusion, during the late acute phase
424 and at convalescence, and shown with respect to days from onset of symptoms and as a
425 group comparison. The black lines connect data points from the same individuals. Wilcoxon
426 test was used to compare the groups separately.
427
428 **Figure 2. Airway IgG and IgA responses to RBD and circulating S-specific memory B cells**
429 **across COVID-19 severity during acute disease and convalescence. a)** Scatter plots of the
430 levels of IgG and IgA to RBD in the upper airway. The black lines indicate median values.
431 Mann-Whitney U was used to compare the groups. **b)** Heat map generated by sorting data
432 according to PDS. The heat map also includes data from PPHC and PCR- as a reference
433 (indicated with PDS 0). Missing data and not available/applicable samples are shown in
434 black. **c)** Comparison of the levels of RBD IgG/A in different upper and lower airway
435 compartments. Data on plasma are shown as a reference. The black lines connect data
436 points from the same individuals. Wilcoxon test was used to compare the groups separately.
437 **d)** Representative example with gating strategy of SARS-Cov-2-specific memory B cells from
438 the four different categories analyzed, and example of further characterization on RBD
439 binding and B cell isotype (IgG+ or IgA+ assumed to correspond to IgD-IgM-IgG- B cells). **e)**
440 Scatter plot shows the quantification of S-specific memory B cells in matched acute (filled)
441 and convalescent (filled with black lining) PBMCs in relation to days in the subset of
442 individuals analyzed color-coded according to PDS. **f)** Pie charts showing the cumulative
443 characterization of RBD binding and memory B cell isotypes. The dotted lines on a) and e)
444 indicate the average background level from PPHC. In a) the line overlaps with not detected
445 (ND) for IgG levels.
446
447


a
Study cohort (n=147)
AS/Mild (n=19)
Moderate (n=58)
Severe (n=58)
Fatal (n=12)
Pre-pandemic Healthy Controls (n=30)
Possibly exposed PCR- (n=9)
Timeline
Acute disease
0 - 54 days
Convalescence
46 - 168 days
Sampling
Blood
Plasma
IgG & IgA
PBMC
Memory B cells
Airways
Nostril swab
Nasopharyngeal aspirate
Endotracheal aspirate
IgG & IgA B cells
b
N
S
RBD
Plasma IgG (OD)
Plasma IgA (OD)
Peak disease severity
1
2
3
4
5
6
7
Acute (n=19)
Conv (n=18)
Acute (n=58)
Conv (n=57)
Acute (n=58)
Conv (n=52)
Acute (n=12)
c
R=0.7/P<0.0001 (n=147)
R=-0.2/P=0.03 (n=139)
R=0.2/P=0.02 (n=147)
R=-0.1/P=0.1 (n=139)
Days from onset of symptoms
d
(n=15)
Late acute
Convalescent
Study inclusion
RBD IgG (OD)
Days from onset of symptoms
e
(n=15)
RBD IgG (OD)
Study inclusion
Late acute
Convalescent

Figure 1


a
Nostril swabs (NSW)
RBD IgG (OD)
RBD IgA (OD)
Nasopharyngeal aspirates (NPA)
Acute (n=13)
Conv (n=9)
Acute (n=42)
Conv (n=49)
Acute (n=30)
Conv (n=36)
Acute (n=4)
Acute (n=10)
Conv (n=9)
Acute (n=6)
Conv (n=34)
Acute (n=13)
Conv (n=29)
Acute (n=5)
b
Plasma
Airways(NSW/NPA/ETA)
Acute
Conv
IgG
IgA
PDS
VL
Days - Acute
Days - Conv
Mild/AS
Moderate
Severe
Fatal
PCR-
Pre-Pandemic
Peak disease severity
Ct value (VL)
Days from sympt - Acute
Days from sympt - Conv
OD
c
RBD IgG
RBD IgA
OD
NSW
NPA
ETA
Plasma
(n=13)
p=0.09
d
Lymphocytes → Single → Live; CD3/14/16/56- →CD19+CD20+ → IgD-IgM-
FSC
FSC (Height)
FSC (Area)
7AAD
CD20 BV605
CD19 ECD
IgD FITC
IgM PerCP-Cy5.5
PPHC
PCR-
AS/Mild
Mod/Severe
0.0036
0.0078
0.60
1.35
Spike PE
Spike APC
SSC
28.7
RBD BV421
5.26
94.7
IgG BV786
(Convalescent phase)
e
Spike+ switched memory B cells
% of CD19/20+ IgD/M-
Days from onset of symptoms
Peak disease severity
(n=6)
(n=5)
(n=1)
(n=2)
PPHC (n=6)
f
S/RBD
IgG/IgA
AS/Mild
Mod/Severe
16
84
11
89
(n=6)
21
79
6
94
(n=8)
RBD
Spike
(IgA)
IgG
(Convalescent phase)

Figure 2